Axsome Therapeutics Inc

AXSM

Healthcare|Biotechnology|USA

$233.80

-15.15 (-6.09%)

Tangible Book

$0.07

Upcoming Data Readouts (5)

Dec 2026

Est. completion

P2Multiple Sclerosis

Solriamfetol for the Treatment of Multiple Sclerosis Fatigue

Dec 2026

Est. completion

P3Excessive Sleepiness

Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)

Mar 2028

Est. completion

P3Fibromyalgia

Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design

Dec 2028

Est. completion

P3Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms

Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol

Sep 2029

Est. completion

Narcolepsy

SUNOSI® (Solriamfetol) Pregnancy Registry